Neoplasia III Flashcards
androgen receptor gene
AR
-used to determine tumor clonality
clonality in lymphocytes
look at Ig and T cell receptor rearrangements
haploinsufficiency
loss of gene function due to loss of single allele
tumor suppressor genes
must lose both alleles
proto-oncogenes
only need to lose one allele
X-linked markers
females are mosaics of X inactivation
- can assess the clonality of cancer based on this
- examine the X-linked genes
fundamental changes resulting in malignant phenotype
self-sufficient growth signaling - no external stimuli
insensitive to growth inhibitor signals - TGF-beta and CDKIs
evasion of apoptosis - inactivate p53
limiteless potential
sustained angiogenesis
ability to evade and metastasize
defects in repair of DNA
oncogenes
from mutations in proto-oncogenes
ability to promote cell growth in absence of growth signals
oncoproteins
products of oncogene
proto-oncogene
in normal cell
-growth factors, or their receptors, signal transducers, transcription factors, cell cycle components
-mutations gives rise to oncogenes
steps in cell proliferation
1 binding growth factor
2 activation of GF receptor - signal transduction across membrane
3 transmission of signal across cytosol
4 nuclear regulatory factors initiate transcription
5 entry into cell cycle
self-sufficiency in growth
oncogenes - oncproteins
growth factor signaling
often paracrine
cancer cell growth factors
can become autocrine
glioblastoma growth factor
express both PDGF and PDGF receptor
-autocrine signaling
growth factor receptors
tyrosine kinases
-usually transiently activated
oncigenic grwoth factor receptors
constitutive dimerization and activation
neuroendocrine growth factor receptor
RET receptor
-in parafollicular C cells of thyroid, adrenal medulla, parathyroid cell precursors
mutations - MEN types 2a and 2b
MEN 2a
mutation in RET extracellular domain
- constitutive dimerization
- medullary thyroid carcinomas and adrenal and PT tumors
MEN 2b
mutation in RET cytoplasmic domain
- alter specificity of tyrosine kinase
- thyroid and adrenal tumors
- no parathyroid involvement
FLT3
FMS-like tyrosine kinase 3 receptor
- mutation can lead to constitutive signaling
- detected in myeloid leukemias
gastrointestinal stromal tumors
constitutively activating mutation in c-KIT or PDGFR
ERBB1
receptor for EGF
- overexpressed in squamous cell carcinoma of lung
- also tumors of head and neck
ERBB2
receptor for EGF
-overexpressed in breast cancer and adenocarcinoma of ovary, lung, stomach, and salivary gland